CN1052868A - 利用天然神经节苷脂或其衍生物来稳定并维持神经生长因子的生物学活性 - Google Patents

利用天然神经节苷脂或其衍生物来稳定并维持神经生长因子的生物学活性 Download PDF

Info

Publication number: CN1052868A
Authority: CN; China
Prior art keywords: sialo; sphingolipids; complex compound; ngf; acid
Prior art date: 1989-11-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

CN90110048A

Other languages

English (en)

Chinese (zh)

Inventor

弗朗切斯科·德拉·瓦莱

兰弗兰科·卡列加罗

奥雷利奥·罗密欧

阿尔贝特·莱昂

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fidia SpA

Original Assignee

Fidia SpA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-14

Filing date

1990-11-14

Publication date

1991-07-10

1989-11-14 Priority claimed from IT04855589A external-priority patent/IT1238347B/it

1990-11-14 Application filed by Fidia SpA filed Critical Fidia SpA

1991-07-10 Publication of CN1052868A publication Critical patent/CN1052868A/zh

Status Withdrawn legal-status Critical Current

Links

108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 106
150000003408 sphingolipids Chemical class 0.000 title claims abstract description 83
102000015336 Nerve Growth Factor Human genes 0.000 title abstract description 87
230000004071 biological effect Effects 0.000 title abstract description 28
229940053128 nerve growth factor Drugs 0.000 title abstract description 5
150000001875 compounds Chemical class 0.000 claims abstract description 123
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
150000001408 amides Chemical class 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims description 27
239000002253 acid Substances 0.000 claims description 22
238000000034 method Methods 0.000 claims description 22
150000003839 salts Chemical class 0.000 claims description 13
-1 aliphatic ester Chemical class 0.000 claims description 12
150000002270 gangliosides Chemical class 0.000 claims description 9
230000001537 neural effect Effects 0.000 claims description 8
125000002252 acyl group Chemical group 0.000 claims description 6
230000036039 immunity Effects 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 5
125000002723 alicyclic group Chemical group 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
125000000524 functional group Chemical group 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
239000000463 material Substances 0.000 claims description 4
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 3
230000032683 aging Effects 0.000 claims description 3
150000002596 lactones Chemical class 0.000 claims description 3
239000003960 organic solvent Substances 0.000 claims description 3
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 2
CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 2
230000007170 pathology Effects 0.000 claims description 2
230000001684 chronic effect Effects 0.000 claims 4
201000010099 disease Diseases 0.000 claims 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
230000007171 neuropathology Effects 0.000 claims 3
230000035479 physiological effects, processes and functions Effects 0.000 claims 3
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims 2
230000004770 neurodegeneration Effects 0.000 claims 2
208000015122 neurodegenerative disease Diseases 0.000 claims 2
230000006242 butyrylation Effects 0.000 claims 1
238000010514 butyrylation reaction Methods 0.000 claims 1
CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 claims 1
230000035322 succinylation Effects 0.000 claims 1
238000010613 succinylation reaction Methods 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 abstract description 7
108090000623 proteins and genes Proteins 0.000 abstract description 7
150000001733 carboxylic acid esters Chemical class 0.000 abstract description 2
238000004519 manufacturing process Methods 0.000 abstract description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
238000012360 testing method Methods 0.000 description 20
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 12
239000000825 pharmaceutical preparation Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
239000012530 fluid Substances 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
238000013016 damping Methods 0.000 description 9
239000013543 active substance Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
102000007072 Nerve Growth Factors Human genes 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000003900 neurotrophic factor Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000000829 suppository Substances 0.000 description 6
239000004471 Glycine Substances 0.000 description 5
101100404651 Mus musculus Ngf gene Proteins 0.000 description 5
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 5
230000006870 function Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000004062 sedimentation Methods 0.000 description 5
KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 5
229960004982 vinblastine sulfate Drugs 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
238000001261 affinity purification Methods 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000004821 distillation Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000007921 spray Substances 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
239000003708 ampul Substances 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
210000002932 cholinergic neuron Anatomy 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000002674 ointment Substances 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
230000008569 process Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
210000001913 submandibular gland Anatomy 0.000 description 3
238000004804 winding Methods 0.000 description 3
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
241000254171 Curculionidae Species 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
206010036631 Presenile dementia Diseases 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000028600 axonogenesis Effects 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
229940106189 ceramide Drugs 0.000 description 2
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
230000020176 deacylation Effects 0.000 description 2
238000005947 deacylation reaction Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000009413 insulation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
150000002500 ions Chemical group 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000007472 neurodevelopment Effects 0.000 description 2
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical class CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
240000005373 Panax quinquefolius Species 0.000 description 1
235000003140 Panax quinquefolius Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102100024304 Protachykinin-1 Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
241000219161 Theobroma Species 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
229910052728 basic metal Inorganic materials 0.000 description 1
150000003818 basic metals Chemical class 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
230000000574 ganglionic effect Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007792 gaseous phase Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002339 glycosphingolipids Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
102000046917 human NGF Human genes 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical group OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229940098695 palmitic acid Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000005059 placental tissue Anatomy 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
210000000273 spinal nerve root Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
210000000331 sympathetic ganglia Anatomy 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229940070710 valerate Drugs 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
239000011800 void material Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Crystallography & Structural Chemistry (AREA)
Zoology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

CN90110048A 1989-11-14 1990-11-14 利用天然神经节苷脂或其衍生物来稳定并维持神经生长因子的生物学活性 Withdrawn CN1052868A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IT04855589A IT1238347B (it)	1989-11-14	1989-11-14	Stabilizzazione e mantenimento dell'attivita' biologica del fattore di crescita nervoso mediante gangliosidi naturali o loro derivati.
IT48555A/89		1989-11-14
IN954CA1990 IN172427B (2)	1989-11-14	1990-11-13

Publications (1)

Publication Number	Publication Date
CN1052868A true CN1052868A (zh)	1991-07-10

Family

ID=26324373

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN90110048A Withdrawn CN1052868A (zh)	1989-11-14	1990-11-14	利用天然神经节苷脂或其衍生物来稳定并维持神经生长因子的生物学活性

Country Status (8)

Country	Link
EP (1)	EP0433113B1 (2)
JP (1)	JPH03179000A (2)
CN (1)	CN1052868A (2)
AT (1)	ATE122056T1 (2)
AU (1)	AU629714B2 (2)
CA (1)	CA2029965A1 (2)
DE (1)	DE69019122T2 (2)
IN (1)	IN172427B (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1046734C (zh) *	1995-03-24	1999-11-24	中国科学院上海生理研究所	一种含神经节苷脂为主的糖脂类物质的生产方法
CN103083724A (zh) *	2013-01-31	2013-05-08	东华大学	一种负载gm1和ngf双营养因子的神经组织修复支架的制备方法
CN108498523A (zh) *	2017-02-24	2018-09-07	上海交通大学	含不饱和脂肪酸链的神经节苷脂衍生物的制备方法及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5981485A (en) *	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
SE9201073D0 (sv) *	1992-04-03	1992-04-03	Kabi Pharmacia Ab	Protein formulation
IT1259176B (it) *	1992-10-23	1996-03-11	Fidia Spa	Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso
FR2703682B1 (fr) *	1993-04-06	1995-05-12	Atochem Elf Sa	Procédé de préparation de (méth)acrylate(s) d'alkylimidazolidone.
US10709770B2 (en)	2013-07-31	2020-07-14	Mead Johnson Nutrition Company	Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US9609888B2 (en)	2013-07-31	2017-04-04	Mead Johnson Nutrition Company	Nutritional compositions containing synergistic combination and uses thereof
US10582714B2 (en)	2015-07-10	2020-03-10	Mead Johnson Nutrition Company	Nutritional compositions and methods for promoting cognitive development
US10617701B2 (en)	2015-07-10	2020-04-14	Mead Johnson Nutrition Company	Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4716223A (en) *	1981-08-04	1987-12-29	Fidia, S.P.A.	Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
IT1199116B (it) *	1984-07-03	1988-12-30	Fidia Farmaceutici	Derivati di gangliosidi
IT1219839B (it) *	1988-02-08	1990-05-24	Fidia Farmaceutici	Purificazione,caratterizazione e applicazione di un fattore neuronotrofico derivato da cervello di nammifero
US5073543A (en) *	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle

1990
- 1990-11-13 IN IN954CA1990 patent/IN172427B/en unknown
- 1990-11-14 AT AT90403221T patent/ATE122056T1/de not_active IP Right Cessation
- 1990-11-14 CN CN90110048A patent/CN1052868A/zh not_active Withdrawn
- 1990-11-14 DE DE69019122T patent/DE69019122T2/de not_active Expired - Fee Related
- 1990-11-14 EP EP90403221A patent/EP0433113B1/en not_active Expired - Lifetime
- 1990-11-14 JP JP2310148A patent/JPH03179000A/ja active Pending
- 1990-11-14 AU AU66628/90A patent/AU629714B2/en not_active Ceased
- 1990-11-14 CA CA002029965A patent/CA2029965A1/en not_active Abandoned

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1046734C (zh) *	1995-03-24	1999-11-24	中国科学院上海生理研究所	一种含神经节苷脂为主的糖脂类物质的生产方法
CN103083724A (zh) *	2013-01-31	2013-05-08	东华大学	一种负载gm1和ngf双营养因子的神经组织修复支架的制备方法
CN108498523A (zh) *	2017-02-24	2018-09-07	上海交通大学	含不饱和脂肪酸链的神经节苷脂衍生物的制备方法及其应用
CN108498523B (zh) *	2017-02-24	2023-06-20	上海交通大学	含不饱和脂肪酸链的神经节苷脂衍生物的制备方法及其应用

Also Published As

Publication number	Publication date
IN172427B (2)	1993-07-24
CA2029965A1 (en)	1991-05-15
JPH03179000A (ja)	1991-08-02
AU629714B2 (en)	1992-10-08
EP0433113A1 (en)	1991-06-19
DE69019122T2 (de)	1995-10-05
DE69019122D1 (de)	1995-06-08
ATE122056T1 (de)	1995-05-15
AU6662890A (en)	1991-05-23
EP0433113B1 (en)	1995-05-03

Legal Events

Date	Code	Title
1991-07-10	C06	Publication
1991-07-10	PB01	Publication
1993-02-03	C10	Entry into substantive examination
1993-02-03	SE01	Entry into force of request for substantive examination
1997-05-21	C03	Withdrawal of patent application (patent law 1993)
1997-05-21	WW01	Invention patent application withdrawn after publication

Publication	Publication Date	Title
US10017506B2 (en)	2018-07-10	ATX modulating agents
US6589759B1 (en)	2003-07-08	Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
CN1230889A (zh)	1999-10-06	NAALADase组合物和治疗谷氨酸异常及在动物中产生神经元活性的方法
CN1324367A (zh)	2001-11-28	环状前塞波素衍生肽及其应用
CN1452492A (zh)	2003-10-29	神经保护肽
CN1354669A (zh)	2002-06-19	红细胞生成素药物组合物
US8921340B2 (en)	2014-12-30	Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
EP2455099B1 (en)	2016-01-20	Method of producing recombinant TAT-HOXB4H protein for use as a stimulant of hematopoiesis in vivo
CN1882355A (zh)	2006-12-20	保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
JP2019514895A (ja)	2019-06-06	新規な免疫原性ＣＤ１ｄ結合ペプチド
CN1284943A (zh)	2001-02-21	含有γ－谷氨酰基和β－天冬氨酰基的免疫调制剂化合物及其制备方法
CN1420878A (zh)	2003-05-28	具有释放生长激素特性的化合物
CN1568328A (zh)	2005-01-19	新的糖脂及其作为有效成分的用于自体免疫疾病的药物
CN1202112A (zh)	1998-12-16	增强胰腺功能的组合物
EP4295903A2 (en)	2023-12-27	Compositions and methods for treating farber disease
US20120322886A1 (en)	2012-12-20	Use of a saturated amines compound in manufacture of medicaments for mobilizing peripheral blood hematopoietic stem cell
EP0433113B1 (en)	1995-05-03	Stabilization and maintenance of the nerve growth factor biological activity by use of natural gangliosides or derivatives thereof
JP2018530577A (ja)	2018-10-18	神経変性疾患の治療のための方法および組成物
US20260000741A1 (en)	2026-01-01	Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
EA010574B1 (ru)	2008-10-30	Пептид, нормализующий метаболизм в костной и хрящевой тканях, фармацевтическая композиция на его основе и способ ее применения
EP3721799A1 (en)	2020-10-14	Methods of treating brain disorders or identifying biomarkers related thereto
EP4342479A1 (en)	2024-03-27	Composition containing function-reinforced stem cell for prevention or treatment of atopic dermatitis
CN1662242A (zh)	2005-08-31	用于治疗与神经营养蛋白相关和疾病的药物组合物
JP6829225B2 (ja)	2021-02-10	モノアミン産生増加剤としての間葉系幹細胞を含む医薬組成物
TW200819123A (en)	2008-05-01	Methods of treatment using alpha-2-delta-1 selective compounds